Abstract
The long-term evolution of Hu antibody (Hu-Ab) titers in patients with paraneoplastic neurologic syndromes (PNSs) is not known. Described is the evolution of Hu-Ab titers in 35 patients with PNS with a median follow-up of 32 months (range 6 to 108 months). No correlation was observed between Hu-Ab titers and neurologic outcome, tumor evolution, or type of treatment. Serial Hu-Ab determinations are not useful for monitoring the clinical outcome of patients with PNS.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Autoantibodies / blood*
-
Autoantibodies / immunology
-
Autoantigens / immunology*
-
Carcinoid Tumor / complications
-
Carcinoid Tumor / immunology
-
Carcinoid Tumor / therapy
-
Carcinoma, Small Cell / complications
-
Carcinoma, Small Cell / immunology
-
Carcinoma, Small Cell / therapy
-
Disease Progression
-
ELAV Proteins
-
Female
-
Follow-Up Studies
-
Humans
-
Lung Neoplasms / complications
-
Lung Neoplasms / immunology
-
Lung Neoplasms / therapy
-
Male
-
Middle Aged
-
Nerve Tissue Proteins / immunology*
-
Paraneoplastic Syndromes, Nervous System / blood
-
Paraneoplastic Syndromes, Nervous System / immunology*
-
Predictive Value of Tests
-
RNA-Binding Proteins / immunology*
-
Retrospective Studies
-
Treatment Outcome
Substances
-
Autoantibodies
-
Autoantigens
-
ELAV Proteins
-
Nerve Tissue Proteins
-
RNA-Binding Proteins